GlassScriptPhysician profile
Marla Michelle Davis
NPI 1033693320
$1,621.88
in general payments reported to CMS, 2019-2025
27 companies · $18.75 in 2025
The $18.75 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.93 · 2022: $453 · 2023: $557 · 2024: $571 · 2025: $18.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,147.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $300.82 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $178.18 | 2022-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $151.38 | 2022 | |
| Exact Sciences Corporation | $128.51 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.06 | 2022-2024 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $91.49 | 2022-2024 | Otezla, Repatha, Krystexxa |
| Corcept Therapeutics | $75.12 | 2024 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $73.83 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $61.22 | 2022-2024 | Airsupra, Farxiga |
| Pfizer INC. | $51.52 | 2023 | |
| Medtronic, INC. | $46.02 | 2024 | Intellis Adaptivestim |
| Novo Nordisk INC | $42.93 | 2023-2024 | Rybelsus, Ozempic |
| Phathom Pharmaceuticals, INC. | $39.26 | 2024-2025 | Voquezna |
| Abbvie INC. | $34.60 | 2023 | |
| Xeris Pharmaceuticals, INC. | $33.34 | 2022-2024 | Gvoke Hypopen |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $24.12 | 2023 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Indivior INC. | $21.93 | 2021 | |
| Sanofi-Aventis U.S. LLC | $20.83 | 2023 | |
| Becton, Dickinson and Company | $20.62 | 2024 | Bd Max System, Bd Max Instrument |
| Kowa Pharmaceuticals America, INC. | $19.46 | 2022 | |
| Electromed, INC. | $19.32 | 2024 | Smartvest |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.01 | 2024 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $16.20 | 2022 | |
| Pharming Healthcare, INC. | $14.47 | 2024 | Ruconest |
| Biohaven Pharmaceutical Holding Company LTD. | $14.17 | 2022 | |
| Insightec,INC | $13.92 | 2023 | Exablate |
| Merck Sharp & Dohme LLC | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marla Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.